A recent study revealed that the dengue vaccine developed by Brazil's Butantan Institute has maintained an efficacy rate of 80.5% against severe dengue cases after five years. This efficacy rate pertains to situations where the disease presents severe symptoms, such as bleeding and intense abdominal pain. Importantly, during the research, there were eight hospitalizations due to dengue, but none occurred in the vaccinated group, highlighting the vaccine's effectiveness in preventing hospitalizations and serious complications associated with the disease.

The Simply administered vaccine, which is the first single-dose vaccine developed globally for this mosquito-borne disease, showed an overall efficacy rate of 65% against any dengue serotype. This rate exceeds the World Health Organization's expectations, which required a minimum efficacy of 50% for vaccine approval. Researchers from Butantan Institute, along with colleagues from the Tropical Medicine Research Center and Fiocruz, published these findings in the journal Nature Medicine, emphasizing the significance of the vaccine in the global fight against dengue.

As dengue continues to be a public health concern in tropical regions, the sustained efficacy of the Butantan vaccine offers substantial hope for controlling severe outbreaks. The continued success of this vaccination may lead to its broader distribution and acceptance, thereby significantly reducing hospitalization rates and severe cases, which could ease the burden on healthcare systems affected by dengue in Brazil and beyond.